Stock Analysis
Medtronic plc (MDT) Stock Analysis
Medtronic plc (MDT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Medtronic plc (MDT) currently has an AIQ Score of 64/100, indicating a neutral setup. Quality is the strongest factor at 74/100. Momentum is the weakest current factor at 53/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MDT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $90.96 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Neutral |
| Market Cap | $117.82B |
| P/E Ratio | 16.64 |
| Forward P/E | — |
| EPS | $1.15 |
| Revenue TTM | $9.76B |
| Dividend Yield | 0.01% |
| Beta | 0.57 |
| Volume | 5.41M |
| 52-week range | $73.31-$106.33 |
| RSI 14 | 41.28 |
| 50-Day SMA | $87.69 |
| 200-Day SMA | $89.55 |
| Analyst Price Target | $96.48 |
| Next Earnings | Nov 17, 2026 |
MDT
OverviewMDT Stock Analysis Summary
Medtronic plc (MDT) currently has an AIQ Score of 64/100, indicating a neutral setup. Quality is the strongest factor at 74/100. Momentum is the weakest current factor at 53/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, MDT has AIQ Score of 64/100 with Quality base of 74/100 and fading Momentum at 53/100. Wait for component alignment before adding exposure.
Quality (74/100) leads while Momentum (53/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.72% stock move · MDT classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MDT Bullish or Bearish Right Now?
MDT currently has a neutral overall setup. Quality is the strongest factor at 74/100, while Momentum is weakest at 53/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 74/100.
- - Risk Resilience is supportive at 73/100.
- - Price is +3.73% above its 50-day SMA.
- - Analyst target implies +6.07% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (21 vs 20).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
MDT's Technical Analysis Consensus is currently Neutral, with 21 buy, 4 neutral, and 20 sell votes. MDT's 14-day RSI is 41.28, which places the stock in a weaker momentum range. MDT's beta is 0.57, indicating lower market sensitivity than the broad market.
What Changed in MDT?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the MDT Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MDT Decision Framework
Public evidence layers, setup checks, and risk context for Medtronic plc.
Medtronic plc (MDT) Stock Analysis
Medtronic plc has an AIQ Score of 64/100 in a Neutral regime. Quality is strongest at 74/100. Beta is 0.57, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MDT is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that quality leads at 74/100 while momentum lags at 53/100. |
| Factor Evidence | Momentum 53/100 · Value 58/100 · Quality 74/100 · Risk 73/100 · Sentiment 61/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 74/100.
Momentum is 53/100 and RSI (14) is 41.3.
MDT is in a Neutral regime at 64/100.
Risk factor is 73/100 with beta 0.57 and annual volatility 23.43%.
Current conflict: quality leads at 74/100 while momentum lags at 53/100.
MDT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MDT Fundamentals
MDT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MDT Technical Analysis
MDT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MDT Stock Catalysts
Track MDT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MDT Dividend Analysis
MDT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MDT Financial Data
MDT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MDT Risk Analysis
MDT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MDT Stock News
MDT stock news, market tone, recent headlines, and catalyst context.
MDT vs Medical Devices Peers
Current peer cohort: MDT · MTD · NVCR · NVST · OMCL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MDT Current stock | 64/100 | 58/100 | 53/100 | 73/100 | -0.11 | 23.43% | Current |
| MTD Mettler-Toledo | 27/100 | 30/100 | 8/100 | 55/100 | 0.14 | 31.82% | MDT vs MTD |
| NVCR NovoCure | 49/100 | 55/100 | 36/100 | 54/100 | 0.63 | 80.61% | MDT vs NVCR |
| NVST Envista Holdings | 52/100 | 62/100 | 33/100 | 69/100 | 0.63 | 37.56% | MDT vs NVST |
| OMCL Omnicell | 50/100 | 62/100 | 29/100 | 59/100 | 0.23 | 50.99% | MDT vs OMCL |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jul 31, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MDT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MDT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MDT Stock FAQ
What is MDT stock price today?
Medtronic plc's current stock price is $90.96. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MDT bullish or bearish right now?
MDT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MDT's market cap?
MDT's market cap is $117.82B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MDT's current P/E ratio?
MDT's current P/E ratio is 16.64 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MDT's RSI?
MDT's 14-day RSI is 41.28 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MDT above its 50-day and 200-day moving averages?
MDT is 3.73% from its 50-day SMA and 1.58% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MDT's next earnings date?
MDT's next earnings date is currently listed as Nov 17, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MDT pay a dividend?
MDT's dividend yield is 0.01% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.